Roche's Elevidys Shows Major Motor Function Gains in 2-Year DMD Trial Results

EMBARK 2: Delandistrogene Moxeparvovec Shows Sustained Benefits in DMD

The gene therapy delandistrogene moxeparvovec-rokl showed clinically meaningful benefits and disease stabilization at 2 years in patients with Duchenne muscular dystrophy (DMD).

Motor gains with Elevidys, DMD gene therapy, evident for 2nd year

Top-line Phase 3 trial data show ambulatory boys with Duchenne continued with motor improvements two years after a single Elevidys infusion.

Roche’s Elevidys demonstrates significant benefits for DMD patients in Phase 3

The gene therapy improved motor functions in children with Duchenne muscular dystrophy two years after treatment

Roche reports positive topline outcomes from DMD treatment trial

Roche has reported positive topline outcomes from the second year of the multinational Phase III EMBARK trial of Elevidys for treating DMD.The post Roche reports positive topline outcomes from DMD treatment trial appeared first on Clinical Trials Arena.

Sarepta shares two-year DMD study data that could inform European approval decision

Sarepta Therapeutics unveiled new results from the second part of a clinical trial for its Duchenne muscular dystrophy gene therapy Elevidys, showing that patients who received the gene therapy performed better ...

In December, the Court authorized compliance with an agreement between the Federal Government and Roche Brasil for the acquisition of Elevidys